Last reviewed · How we verify
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (CheckMate 7A8)
A randomized multi-arm study evaluating the safety and efficacy of palbociclib and anastrozole with or without nivolumab in participants with ER+/HER2- breast cancer
Details
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 23 |
| Start date | Fri Oct 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Breast Cancer
- Cancer
Interventions
- Nivolumab
- Anastrozole
- Palbociclib
Countries
France, Belgium, Germany, Canada, Puerto Rico, Australia, United States, Spain